Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (NASDAQ: CDXC) appointed Dr. Vilhelm Bohr to its Scientific Advisory Board. Dr. Bohr, a leading researcher in aging and neurodegenerative diseases, has over 590 publications and specialized in the effects of nicotinamide riboside (NR) on age-related conditions. His past research through ChromaDex's External Research Program has resulted in significant findings regarding NR's role in mitochondrial dysfunction and neurodegeneration. Dr. Bohr aims to explore further benefits of NR at ChromaDex.
ChromaDex Corp. (NASDAQ:CDXC) appointed Brianna Gerber as the new Chief Financial Officer, effective January 1, 2023. Gerber has over 20 years of experience in finance and investor relations, having served as Senior VP of Finance at ChromaDex since August 2022. CEO Rob Fried praised her leadership and commitment to achieving an EBITDA-positive business. Gerber expressed excitement about leading the company towards profitable growth and operational efficiency.
ChromaDex Corp. (NASDAQ:CDXC) announced new findings supporting the efficacy of its proprietary Niagen® (nicotinamide riboside or NR) in enhancing neurodegenerative biomarkers associated with aging. A recent peer-reviewed study found that NR supplementation significantly increased NAD+ levels in neuron-derived extracellular vesicles and reduced biomarkers linked to Alzheimer’s disease, like Aβ42. This research builds on previous studies supporting NR’s benefits for cognitive health and sets the stage for future trials, including one focused on older adults with mild cognitive impairment.
ChromaDex Corp. (NASDAQ:CDXC) announced that the U.S. FDA has determined that nicotinamide mononucleotide (NMN) cannot be marketed as a dietary supplement, as it has been first investigated as a drug since November 4, 2022. This decision impacts ChromaDex's NMN offerings, while its proprietary ingredient Niagen®, a form of nicotinamide riboside (NR), remains a viable NAD+ precursor backed by over 20 clinical studies. ChromaDex continues its focus on NAD+ research and has established extensive partnerships for its CERP™ program.
ChromaDex Corp. (NASDAQ:CDXC) reported Q3 2022 net sales of $17.1 million, reflecting a 1% decline from Q3 2021. Strong gross margin stood at 59.8%. The net loss improved to $1.0 million or $(0.01) per share, a significant reduction from $8.8 million in Q3 2021. Adjusted EBITDA loss of $1.2 million shows a $5.1 million improvement. The company anticipates high single-digit revenue growth for 2022, targeting cash flow break-even in Q4. Strategic partnerships in China and with Nestlé Health Science were secured.
ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on November 2, 2022, at 4:30 p.m. ET to discuss its third quarter financial results for the period ending September 30, 2022. The results will be announced in a press release after market hours on the same day. Interested participants are advised to dial in 10 minutes early, with the toll-free number being 1-888-330-2446 and Conference ID 4126168. A replay will be available from 7:30 p.m. ET on November 2 to November 9, 2022.
ChromaDex Corp. (NASDAQ:CDXC) announced that its supplement, Tru Niagen®, received the “Most Popular Brand of the Year Award” at the China International Natural Health & Nutrition Expo on September 20, 2022. This recognition highlights the product's robust research backing and expanding market presence, especially in the cross-border e-commerce sector in China. With a consumer base over 264 million aged 60 and above in China, the demand for healthy aging products is growing. ChromaDex aims to solidify its market leadership through partnerships and enhanced distribution channels.
ChromaDex has announced a new long-term commercial license and supply agreement with Nestlé Health Science that expands their previous supply agreement to include dietary supplements. The deal features a $1.975 million initial purchase commitment for the ingredient Niagen®, along with potential future milestone payments and tiered royalties based on sales. In addition, Nestlé is purchasing 3,816,794 shares of ChromaDex at $1.31 each for gross proceeds of $5 million.
ChromaDex Corp. (NASDAQ:CDXC) announced promising findings from a clinical study published in the Journal of the American College of Cardiology. The study evaluated the safety and tolerability of the company's proprietary Niagen® (nicotinamide riboside or NR) in Stage C heart failure patients. Key results showed that high-dose NR was well-tolerated, nearly doubling whole blood NAD+ levels, enhancing mitochondrial function, and reducing inflammatory markers. This milestone trial opens avenues for future research into NR's therapeutic potential in heart failure.
ChromaDex has established a joint venture to expedite the approval of Tru Niagen® registration in China ("Blue Hat" approval). An investment of
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
